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Tamoxifen is an antiestrogen drug widely utilized for the adjuvant hormonal treatment of breast carcinoma. Its use in the primary
prophylaxis of this disease is currently being proposed. Although the drug has few side effects, its precise action on breast tissue that
has not undergone neoplastic transformation has not been fully elucidated. This prospective, randomized study assessed the estro-
gen activity of tamoxifen on the mammary gland epithelium of premenopausal patients using a quantitative analysis of mammary
epithelium Iysosomes identified by the cytochemical technique of GOMORI for acid phosphatase and by light microscopy. Tamoxifen
significantly increased the number of Iysosomes only during the secretory phase of the menstrual cycle. We concluded that the early
effect of the drug on normal mammary tissue is synergistic with the effect of estrogen during the premenopausal period.
INTRODUCTION
Tamoxifen is considered to be an antiestrogennonsteroid drug that inhibits the growth of breastcarcinoma, thus representing the. drug of choice
for hormonal treatment of this disease.t Recent studies have
shown a lower incidence of primary cancer and cyclic pain
in the contralateral breast of patients with carcinoma treated
with tamoxifen.t-3Thus, it is of great interest to know how
the drug acts upon normal breasts, to the end of it being
used as a primary prophylaxis of breast carcinoma in
women at high-risk for developing this disease.3-S
Lysosomes are cytoplasmic organelIes containing
lytic enzymes and covered with semiperlTIeable
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membranes, and were first studied by DE DUVE et aI.ó
These investigators identified these organelIes by celI
fractionation techniques foIlowed by centrifugation, which
led to the observation of vesicles rich in hydrolytic
enzymes.
Studies relating the mamlTIary gland to lysosomes
have shown a larger number of these organelIes in breast
tUlTIOr ceIls compared to the normal adjacent
parenchyma.7•X Lysosomes are important markers of
estrogen-mediated ceIl proliferation in the breast
parenchyma. 7.X
GIRÃO et aI.,9 studying the numerical variation of
lysosomes in the mammary epithelium during the
menstrual cycle, observed a significantly greater amount
of lysosomes during the first phase than in the second
phase, demonstrating that the number of lysosomes refiects
estrogen activity.
The objecti ve of this study was to assess the estrogen
activity of talTIoxifen on the epitheliulTI of the malTImary
gland of premenopausal WOlTIen by lysosome
qua~tification.
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OBJECTIVE completely tilled with epithelial cells. Data were analyzed
statistically by the Mann-Whitney and Fisher exact tests.13
RESULTS
Tamoxifen is the most wielely-used elrug for
chemoprophylaxis of breast carcinoma. However, its action
on the norlnal mammary lobule before and after
menopause is still unknown.14-ló
It is difficult to create an experimental modeI that
will. reproduce the complex endocrine interaction of the
hUlnan breast, and there are obvious ethicaI restrictions
with re.spect to taking biopsies froln the nOrInal breast.
Tamoxifen significantly increased the number of
lysosomes in the mammary epithelium during the second
phase of the menstrual cycle (Figs. 1 and 2).
During tamoxifen administration, the number of
lysosomes remained stable in both phases of the menstrual
cycle (Table 1).
Progesterone leveIs were significantly higher in
group B patients during the Iuteal phase of the menstrual
cycle (Table 2).
MATERIALS ANO METHOOS
To evaluate quantitatively the lysosomes of the
human malnmary gland epithelium in the proliferative and
secretory phase of the menstrual cycle during tamoxifen
administration, and to compare the values obtained with
those detected in untreated women during these same
phases.
The study was carried out on 33 women aged 15-37
with fibroadenomas ] -3 cm in diameter which were
removed and submitted to biopsy. Normal parenchyma
samples were obtained from breast tissue situated at least
2 cm from the fibroadenoma at the time of surgical exeresis
under local anesthesia. AlI patients gave informed written OISCUSSION
consent and the study was approved by the Ethics
Committee of Hospital São Paulo.
The patients were divided randomly into two groups:
Group A (controI) consisted of 16 patients, and Group B
consisted of 17 patients who took tamoxifen (20 mg/day)
for 30 days before surgery.
All patients had normal menstrual cycles. The cycle
phase was characterized on the basis of the date of last
menstruation and measurement of plasma progesterone.
Patients with endocrine disease, pregnant patients or those
who had taken hormones during the
prior 12 months were excluded from
the study, as were also patients whose
biopsy did not confirm the presence
of a fibroadenoma in the nodule or
normality of the adjacent parenchyma.
The chüice of menstrual cycle
phase for exeresis of the nodule was
aleatory for both groups, but the dates
were fixed for a period between the
7th and 10th day during the fir~t
phase, and between the 21 st and 23rd
day during the second.
Lysosolnes were identified by the
cytochemical method of aciel
phosphatase detection, lO anel. counts
were carrieel out using the PRICOLI"
anelMARTINS 12 methoels. Counts were
Figure 1 - Photomicrograph of a histological section of human mammary gland epithelium
carrieel out in a double-blind manner on during the secretory phase from a patient NOT treated with tamoxifen (Gomori method
25 reticulated areas per 400x field for acid phosphatase. Magnification.:t 1.440 X).
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Secretory
Ucalc=12*
Ucrit= 12
tissues. The lnethod used for breast
tissue is reproducible as demonstrated
by ZAMITH et a1.20and GIRÃO et alY
These investigators observed a larger
number of lysosomes during the first
phase of the cycle in breast tissue from
premenopausal women, in agreelTIent
with the serum leveI of estradiol.
Tamoxifen adlninistered before
menopause first causes an increase in
serum estrogen and progesterone leveIs,
possibly initialing the proliferation of
. the maITImary epithelium.21 The
increased number of lysosolnes
observed during the second phase of the
cycle in women taking tamoxifen
confirms the estrogen agonist effect of
the drug on premenopausal WOITIen.
On the other hand, the increased
concentration of active serum
progesterone acti vates the enzyme 17-
beta-hydroxysteroid oxidoreductase,
which favors the conversion of estrone
to estradiol in breast tissue, which in
turns increases estrogen activity.22
Recent studies using ITIolecular
techniques have demonstrated alterations. in the gene
expression of the estradiol receptors which ITIayexplain
the anti proliferati ve action of taInoxifen despite the agonist
estrogen acti vity.23.24
The explanation of the antiproliferative effect on the
breast dllring long-tenn treatnlent lnay be clown-reglllation
123
Group A x B
Proliferative
Ucalc= 28
Ucrit= 15
Group B
Proliferative Secretory
86 75
104 126
131 113
121 136
137 113
117 139
150 175
141 134
188
133
2nd)
99
Group A
Proliferative Secretory
147 94
131 131
138 81
119 87
128 85
140 115
169 106
101
131
133
The tissue fragment utilized in the present study was
obtained froIn patients with fibroadenoma who did not
respond to tamoxifen treatment, after authorization by the
MedicaI Ethics Committee of Hospital São Paulo.
There are numerous. theories attelnpting to explain
the antiproliferative action ofthis drug on neoplastic tisslle.
The major lnechanisln of action,
however, is thought to be the
combination of talTIoxifen with
nuclear estrogen receptor protein
(ERP), which produces a G] block
and decreases production of growth-
stimulating proteins such as
transforming growth factor alpha
(TGF-a), and stimulation of growth-
inhibiting proteins like transfonning
growth factor beta (TGF-B).17-19
TaITIOxifen is predominantly a
tumoristatic agent; it doubles the
leveIs of sex horlnone-binding
globulin (SHBG) and may therefore
exert its antiestrogen effect by Inaki ng
it unavailable to breast cells.\
The quantitative variation in Figure 2 - Photomicrograph of a histological section of human mammary gland epithelium
intracellular lysoSOITIeS indirectly during the secretory phase from a patient treated with tamoxifen (Gomori method for
measures estrogen activity on target acid phosphatase. Magnification.:t 1.4440 X).
Mean
Mann-Whitney Test
1st) Proliferative x secretory
Group A Group B
Ucalc= 6* Ucalc=32
Ucrit= 12 Ucrit= 15
Table 1
Number of Iysosomes in the breast epithelium of patients from Group
A (control) and Group B (tamoxifen) during the proliferative and
secretory phases of the cell cycle.
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Table2
Serum progesterone leveis (nglml) in patients from Group A (control) and
Group 8 (tamoxifen) during the proliferative and secretory phases of the
menstrual cycle.
GroupA
0.4
0.9
0.4
0.7
0.6
0.4
0.5
0.7
0.3
0.54
Mann-Whitney Test
1st) Proliferative
GroupAx 8
Ucale=31
Ucrit= 15
Group8
0.5
0.8
0.5
0.6
0.8
0.3
0.1
0.1
0.46
2) Secretory
Group Ax 8
Ucalc=6*
Ucrit= 12
GroupA
6.1
7.9
6.5
6.5
12.7
4.0
16.3
8.5
Group8
8.9
13.7
24.6
6.8
18.9
36.9
34.2
47.0
33.0
24.89
of estrogen receptors, reduction ofTGF-a
and increase of TGF-B.
Future studies on patients using
talnoxifen for long periods of tilne are
needed to better evaluate the endocrine
effect of the drug on normal breast tissue,
thus pennitting a Inore rational indication
of the drug for treatlnent of benign
diseases and for cancer chelnoprophylaxis.
CONCLUSION
We conclude that talnoxifen
significantly increased the nUlnber of
lysosomes in the Inammary epithelium in
the second phase of the lnenstrual cycle,
with leveIs similar to those detected in the
proliferative phase for both groups. Thus,
the drug appears to have a synergistic
effect with estrogen during the
prelnenopausal period.
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